Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can You Hear That Whistle Blow? Sales Force Reductions Come with Risks

This article was originally published in RPM Report

Executive Summary

Pfizer's big sales force cuts mark the beginning of a disarmament in sales infrastructure across the pharmaceutical industry. That means a lot of sales reps will be out of work-and looking for payback.

You may also be interested in...



The "Super FDA": State Attorneys General Flex Their Muscle in Pharma Enforcement

States have become more aggressive in pursuing pharma for health care fraud. They are building stronger cases by teaming up with each other and the federal government to push companies to accept more onerous restrictions on their business practices.States have become more aggressive in pursuing pharma for health care fraud. They are building stronger cases by teaming up with each other and the federal government to push companies to accept more onerous restrictions on their business practices.

Bextra Settlement Coming Soon: Industry Should Brace for Impact

Record setting $2.3 billion payment is afterthought in context of Pfizer/Wyeth merger, but the Bextra and recent Zyprexa settlement will have far-reaching implications. In economic terms, the first two cases of 2009 exceed the total recoveries of the last 13 pharma marketing settlements. But the big impact may be political: the cases involve a volatile mix of marketing abuses and drug safety

The "Super FDA": State Attorneys General Flex Their Muscle in Pharma Enforcement

States have become more aggressive in pursuing pharma for health care fraud. They are building stronger cases by teaming up with each other and the federal government to push companies to accept more onerous restrictions on their business practices.States have become more aggressive in pursuing pharma for health care fraud. They are building stronger cases by teaming up with each other and the federal government to push companies to accept more onerous restrictions on their business practices.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS080160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel